Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

26 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Companies

Top Ten Companies // Browse A - Z of companies

  • Merck KGaA (Merck)
  • Merck (Merck KGaA)
  • Pfizer
  • Roche
  • Novartis
  • GlaxoSmithKline (GSK)
  • GSK (GlaxoSmithKline)
  • Bristol-Myers Squibb
  • Lilly
  • Bayer

Browse the A - Z of Companies

  • #
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

J

  • J B Chemicals & Pharmaceuticals
  • Jain An Pharmaceuticals
  • Jamjoon Pharmacy
  • Jamp Pharma
  • Janssen
  • Janssen Biotech
  • Janssen Pharmaceutica
  • Janssen-Cilag
  • Japan Tobacco
  • Javelin
  • Jazz Pharmaceuticals
  • JB Chemicals & Pharmaceuticals
  • JCR Pharmaceuticals
  • Jenapharm
  • Jennerex
  • JHP Pharmaceuticals
  • Jiangsu Hengrui Medicine
  • Jiangsu NHWA
  • Jilin Boda
  • Johnson & Johnson
  • JSW Life Sciences
  • Jubilant
  • Julphar
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS